ADC Therapeutics SA (ADCT)vsUnited Therapeutics Corporation (UTHR)
ADCT
ADC Therapeutics SA
$1.10
-0.90%
HEALTHCARE · Cap: $161.53M
UTHR
United Therapeutics Corporation
$525.82
+0.21%
HEALTHCARE · Cap: $22.47B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 3904% more annual revenue ($3.17B vs $79.17M). UTHR leads profitability with a 40.6% profit margin vs -173.0%. UTHR earns a higher WallStSmart Score of 57/100 (C).
ADCT
Avoid23
out of 100
Grade: F
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADCT.
Margin of Safety
+2.4%
Fair Value
$487.34
Current Price
$525.82
$38.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -706.0% — below average capital efficiency
Revenue declined 9.5%
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ADCT
The strongest argument for ADCT centers on Debt/Equity.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : ADCT
The primary concerns for ADCT are EPS Growth, Market Cap, Return on Equity.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
ADCT profiles as a turnaround stock while UTHR is a declining play — different risk/reward profiles.
ADCT carries more volatility with a beta of 1.88 — expect wider price swings.
UTHR is growing revenue faster at -1.6% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (57/100 vs 23/100), backed by strong 40.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADC Therapeutics SA
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
Visit Website →United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?